Contact

Our portfolio

AMI Pharma

AMI Pharma develops therapeutics compounds for Type 1 Diabetes and autoimmune diseases. Their research, based on IP from Amsterdam UMC and Wageningen University & Research, aims to bring new treatments to the clinical trials. AMI Pharma leverages extensive pre-clinical and clinical data to advance their therapeutic pipeline.

  • Institute: Amsterdam UMC
Industry: Diabetes, Metabolic Disorders, Therapeutics
  • Founding year: 2022
Visit website

Want to get in contact about AMI Pharma?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

ikHerstel
Speeding up post-surgical rehabilitation with a personalized e-health recovery platform.
Inreda Diabetic
Improving diabetes management with the AP, a closed-loop bi-hormonal artificial pancreas.
InSteps
Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.
Hipper Therapeutics
Boosting recovery and confidence in elderly hip fracture patients with data-driven rehabilitation technology.
ikHerstel
Speeding up post-surgical rehabilitation with a personalized e-health recovery platform.
Inreda Diabetic
Improving diabetes management with the AP, a closed-loop bi-hormonal artificial pancreas.
InSteps
Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.
Hipper Therapeutics
Boosting recovery and confidence in elderly hip fracture patients with data-driven rehabilitation technology.
Explore full AAV portfolio
Contact